Steventon, L;
Man, Kenneth KC;
Nicum, S;
Miller, R;
Hasson, S;
Shah, S;
Baser, M;
... Chambers, P; + view all
(2024)
The impact of inter-cycle treatment delays on overall survival in patients with advanced-stage ovarian cancer.
The Oncologist
10.1093/oncolo/oyae201.
(In press).
Preview |
Text
Man_The impact of inter-cycle treatment delays on overall survival in advanced-stage ovarian cancer patients_AOP.pdf Download (765kB) | Preview |
Abstract
INTRODUCTION: Chemotherapy forms the cornerstone of systemic treatment for advanced ovarian cancer, extending overall survival; however, drug-related toxicity can lead to treatment delays, potentially diminishing treatment efficacy. This study evaluated the impact of treatment delays on all-cause mortality of patients with ovarian cancer, to better inform decisions on patient management. METHODS: This retrospective, population-based cohort study included 1517 women with advanced-stage ovarian cancer, receiving first-line adjuvant or neoadjuvant chemotherapy in 2014 and 2015. The frequency of inter-cycle delays >7 days was calculated using drug administration dates. Kaplan-Meier estimates were used to compare 2-year overall survival (OS) between patients who were delayed and those treated to schedule. Cox proportional hazards regression was used to investigate the impact of treatment delay on all-cause mortality. Inverse probability of treatment weighting propensity scores were used to adjust for confounding variables. RESULTS: Delays >7 days occurred in 35.3% of patients. Two-year OS probability was 62.7% in patients who experienced treatment delays >7 days (95% CI, 58.7-66.9) compared to 69.1% in those treated to schedule (95% CI, 66.2-72.0). Delays were not significantly associated with all-cause mortality when adjusted for confounders (HR 1.00 95% CI, 0.83-1.20, P = .9). CONCLUSIONS: Delays to chemotherapy treatment were not significantly associated with worsened survival in patients with advanced-stage ovarian cancer. These results can inform clinical decision making that prioritize toxicity management and quality of life for those treated with chemotherapy.
| Type: | Article |
|---|---|
| Title: | The impact of inter-cycle treatment delays on overall survival in patients with advanced-stage ovarian cancer |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1093/oncolo/oyae201 |
| Publisher version: | https://doi.org/10.1093/oncolo/oyae201 |
| Language: | English |
| Additional information: | © The Author(s) 2024. Published by Oxford University Press. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). |
| Keywords: | cancer, ovarian, chemotherapy, treatment, delay, survival |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy > Practice and Policy |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10196485 |
Archive Staff Only
 |
View Item |
